[1] Sanofi Aventis Singapore Pte Ltd 38, Global Med Evidence Generat MEG Lead, Influenza Sanofi Pasteur, Med Influenza Franchise,Sanofi Pasteur, Beach Rd 18-11,South Beach Tower, Singapore 1811, Singapore
[2] Univ Claude Bernard Lyon 1, Lyon, France
[3] CVA, Paris, France
[4] Asia Pacific Alliance Control Influenza APACI, Melbourne, Vic, Australia
[5] Australian Immunisat Coalit, Melbourne, Vic, Australia
[6] Univ Otago, Christchurch, New Zealand
[7] Canterbury Hlth Labs, Christchurch, New Zealand
[8] Griffith Univ, Dept Publ Hlth, Victoria, Australia
[9] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen, Peoples R China
[10] Univ Putra, Chair Malaysia Influenza Working Grp MIWG, Seri Kembangan, Malaysia
[11] Natl Ctr Infect Dis NCID, Singapore, Singapore
[12] Paediat Soc New Zealand Infect & Immunizat Specia, Christchurch, New Zealand
[13] Sanofi Pasteur, Global Med Affairs, Singapore, Singapore
[14] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[15] Sanofi Pasteur, Publ Affairs, Singapore, Singapore
[16] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands
[17] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Gen Practice, Med Ctr, Amsterdam, Netherlands
[18] Hosp Civils Lyon, Unite Hyg Epidemiol Infectiovigilance & Prevent, Lyon, France
[19] Univ Claude Bernard Lyon 1, CNRS Unite Mixte Rech 5308, Ecole Natl Super Lyon,PHE3ID, Inst Natl Sante & Rech Med U1111,Ctr Int Rech Inf, Lyon, France